GV has supported the initial tranche of a $75m series A round for Forty Seven, an immuno-oncology spinout of Stanford University.
US-based cancer therapy developer Forty Seven obtained the first half of a $75m series A round yesterday from a consortium featuring GV, the corporate venturing arm of conglomerate Alphabet.
The round was co-led by Lightspeed Venture Partners and Sutter Hill Ventures and also featured Clarus Ventures. The investors have committed to providing the full amount, though details on conditions for the final close have not been revealed.
Forty Seven officially launched yesterday as a spinout of Stanford University, from which…
